focus -WSS

focus

author：comprehensive 2025-10-02 20:49:12 - browse：9256

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Feed a cold, starve a fever? Here’s what science says

WSS

Readout LOUD podcast: Merger Mondays, Ozempic panic

What the Wegovy shortage looks like for doctors — and for patients

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Massive project maps cells in human brain in unprecedented detail

Medicare to cover more brain scans related to Alzheimer’s drugs

Wikipedia

focus

entertainment

Bright Health sells Medicare Advantage business to Molina

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

In age of alternative facts, a scholarly course on calling out crap

STAT Readout Newsletter: Today in biotech, life science news

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Readout: Today's biotech news includes Sana and Amylyx

DIEP, the 'gold standard' of breast reconstruction, is under threat

Nick Jonas talks about managing diabetes along with his career

Heart attack and stroke risk calculators need revising

Researchers CRISPR chickens in bid to protect them from bird flu

hotspot

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

European regulators recommend Amylyx's ALS drug be rejected

Failure, not just success, should guide future doctors

NFL doctors' conflicts of interest could endanger players, report says

Massive project maps cells in human brain in unprecedented detail

Paxlovid rebound happens. Why and to whom are still a mystery

hotspot

focus

hotspot

focus